AATD is a rare genetic disorder that can severely damage the liver and lungs of affected individuals. The trial will start dose escalation in healthy volunteers (Part A)
The randomized, double-blinded, placebo-controlled trial will be conducted at sites in the US, Canada and Europe. The trial is designed to evaluate MM-141 in combination with nab-paclitaxel and
Ora is a US-based global, full-service ophthalmic clinical research and product development company. As part of the deal, Ora will lead the clinical development of PRT2671, and the
The therapeutic potential will be unlocked by combining ArQule’s chemistry and drug development expertise with Beryllium’s discovery platforms, which integrate structure-guided drug discovery, biophysics and cell biology. The
The Irish firm paid $101 per share to acquire Auspex’s portfolio of new medicines for people who live with movement disorders. Auspex’s lead product candidate SD-809 (deutetrabenazine) is
Around 5,000 individuals with systemic lupus erythematosus (lupus) will be enrolled in the trial to help better understand the genetics of lupus. Also involved in this collaboration is
As part of the deal, Bayer will further develop and commercialize ISIS-FXIRx in areas of high unmet medical need. Under the clinical development program, Bayer will evaluate the
AQX-1125 is a small molecule activator of SHIP1 suitable for oral, once daily dosing and it has been evaluated in multiple preclinical studies and clinical trials. The randomized,
The joint collaboration will focus on biomarkers that may facilitate therapeutic approaches targeting alpha-synuclein, a protein potentially involved in the onset and progression of PD. MJFF CEO Todd
Sovaldi is indicated to treat chronic hepatitis C infection as a component of a combination antiviral treatment regimen. In February 2015, Gilead appointed Mylan as its exclusive distributor
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.